期刊文献+

可溶性ST2对急性ST段抬高型心肌梗死患者临床预后的预测价值 被引量:3

Predictive value of soluble ST2 in clinical prognosis of patients with acute ST-segment elevation myocardial infarction
在线阅读 下载PDF
导出
摘要 目的探讨可溶性ST2(sST2)水平对急性ST段抬高型心肌梗死(STEMI)患者6个月内发生心力衰竭或心源性死亡的预测价值。方法选择就诊于我院心内科并确诊为STEMI患者117例,入院时采用酶联免疫吸附法测定患者血浆sST2水平,随访并记录6个月内MACE(定义为新发心力衰竭或心源性死亡)发生情况。依据是否发生MACE分为MACE事件组与非MACE事件组,分析两组一般资料,并行COX多因素回归分析STEMI患者发生MACE的独立危险因素。结果117例STEMI患者随访6个月内,发生心力衰竭20例,心源性死亡2例。Spearman相关分析结果显示,基线sST2与基础心率、cTnT峰值、Killip分级、NT-proBNP呈正相关(r=0.253、0.335、0.401、0.467,P<0.05),与LVEF呈负相关(r=-0.201,P<0.05)。多因素COX回归分析提示基线sST2值是STEMI患者发生MACE事件的独立危险因素(HR=1.817,P=0.001);而LVEF、cTnT峰值也可独立预测患者MACE事件的发生(HR=0.818、1.328,P=0.003、0.001)。结论基线sST2水平与STEMI患者的临床预后有关,可独立预测患者6个月内MACE的发生风险。 Objective To investigate the predictive value of serum soluble ST2(sST2)level on heart failure or cardiac death in patients with acute ST-segment elevation myocardial infarction(STEMI)within 6 months.Methods A total of117 patients with STEMI were confirmed in the cardiology department of our hospital.The plasma ST2 level was measured by enzyme-linked immunosorbent assay(ELISA)at admission.The occurrence of MACE(defined as new heart failure or cardiac death)was followed up and recorded within 6 months.According to the occurrence of MACE,the patients were divided into MACE event group and non-MACE event group.The general data of the two groups were analyzed,and the independent risk factors of MACE in STEMI patients were analyzed by COX multiple factor regression.Results During the follow-up of 117 patients with STEMI for 6 months,20 cases developed heart failure and2 cases cardiac died.The Spearman correlation analysis showed that baseline sST2 were positively correlated with basal heart rate,cTnT peak value,Killip grade,NT-proBNP(r=0.253,0.335,0.401,0.467,P<0.05),and negatively correlated with LVEF(r=-0.201,P<0.05).The multivariate COX regression analysis showed that the baseline sST2 was an independent risk factor for MACE in STEMI patients(HR=1.817,P=0.001),while LVEF and cTnT peak value can also independently predict the occurrence of MACE events(HR=0.818,1.328;P=0.003,0.001).Conclusion Baseline s ST2 level is associated with clinical prognosis in STEMI patients and can independently predict the risk of MACE in patients within 6 months.
作者 刘祥 丁晓梅 LIU Xiang;DING Xiao-mei(Internal Medicine-Cardiovascular Department,Anhui Provincial Hospital Affiliated to Anhui Medical University,Hefei 230001,China)
出处 《临床医学研究与实践》 2020年第15期1-3,6,共4页 Clinical Research and Practice
基金 2015年安徽省公益性研究联动计划项目(No.15011d04017)。
关键词 可溶性ST2 急性ST段抬高型心肌梗死 主要不良心血管事件 soluble ST2 acute ST-segment elevation myocardial infarction major adverse cardiovascular events
作者简介 刘祥(1994-),男,汉族,安徽涡阳人,硕士在读。研究方向:冠心病危急重症;通讯作者:丁晓梅,E-mail:dingxiaomei-1209@163.com.
  • 相关文献

参考文献1

二级参考文献22

  • 1Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST- segment elevation myocardial infarction. J Am Coll Cardiol 2000; 36: 970-1062.
  • 2Weinberg EO, Shimpo M, De Keulenaer GW, MacGillivray C, Tominaga S, Solomon SD, et al. Expression and Regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 2002; 106: 2961-2966.
  • 3Shimpo M, Morrow DA, Weinberg EO, Sabatine MS, Murphy SA, Antman EM, et al. Serum levels of the interleukin- 1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 2004; 109: 2186-2190.
  • 4Sabatine MS, Morrow DA, Higgins LJ, MacGillivray C, Guo W, Bode C, et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial Infarction. Circulation 2008; 117: 1936-1944.
  • 5Dhillon OS, Narayan HK, Quinn PA, Squire IB, Davies JE, Ng LL. Interleukin 33 and ST2 in non-ST elevation myocardial infarction: Comparison with Global Registry of Acute Coronary Events Risk Scoring and NT-proBNP. Am Heart J 2011; 61:1163-1170.
  • 6Weir RA, Miller AM, Murphy GE, Clements S, Steedman T, Connell JM, et al. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardio12010; 55: 243-250.
  • 7Eggers KM, Armstrong PW, Califf RM, Simoons ML, Venge P, Wallentin L, et al. ST2 and mortality in non-ST-segment elevation acute coronary syndrome. Am Heart J 2010; 159: 788- 794.
  • 8Granger CB, Goldberg R J, Dabbous O, Pieper KS, Eagle KA, Cannon CP, et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 2006;163: 2345-2353.
  • 9Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1 like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005; 23:479- 490.
  • 10Kohli P, Bonaca MP, Kakkar R, Kudinova AY, Scirica BM, Sabatine MS, et al. Role of ST2 innon-st-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial. Clin Chem 2012; 58: 257-266.

共引文献28

同被引文献51

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部